PTCT

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ce06d217.1784383875.ac0f79a1

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

PTC THERAPEUTICS, INC._February 19, 2026 0001070081false00010700812026-02-192026-02-19 ​ ​

UNITED STATES

​

SECURITIES AND EXCHANGE COMMISSION

​

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​ Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): February 19, 2026 ​

PTC THERAPEUTICS, INC.

​ (Exact Name of Company as Specified in Charter) ​ ​

​

​

​

​

Delaware ​ ​ ​ 001-35969 ​ ​ ​ 04-3416587

(State or Other Jurisdiction ​ (Commission ​ (IRS Employer

of Incorporation) ​ File Number) ​ Identification No.)

​ ​ ​

​

​

​

500 Warren Corporate Center Drive ​ ​ ​ ​ ​

Warren, NJ ​ ​ 07059

(Address of Principal Executive Offices) ​ ​ (Zip Code)

​ Registrant’s telephone number, including area code: (908) 222-7000 ​ Not applicable (Former Name or Former Address, if Changed Since Last Report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered

Common Stock, $0.001 par value per share ​

PTCT

​ Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​

Item 2.02. Results of Operations and Financial Condition. On February 19, 2026, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02. Item 7.01. Regulation FD Disclosure. The Company will host a conference call on February 19, 2026 at 4:30 p.m. eastern time, as previously announced. During this call the Company expects to review financial results for the quarter and fiscal year ended December 31, 2025, as well as other corporate highlights and updates. Instructions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto. The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report. Item 9.01. Financial Statements and Exhibits. (d) Exhibits ​

​

​

Exhibit No. ​ ​ ​ Description

99.1 ​ Press Release, dated February 19, 2026 issued by PTC Therapeutics, Inc.

104 ​ The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

​ ​

​ Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ​

​

​

​ PTC Therapeutics, Inc.

​ ​

Date: February 19, 2026 By: /s/ Pierre Gravier

​ Name: Pierre Gravier

​ Title: Chief Financial Officer

​ ​

PTC THERAPEUTICS, INC._January 12, 2026 0001070081false00010700812026-01-122026-01-12 ​ ​

UNITED STATES

​

SECURITIES AND EXCHANGE COMMISSION

​

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​ Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): January 12, 2026 ​

PTC THERAPEUTICS, INC.

​ (Exact Name of Company as Specified in Charter) ​ ​

​

​

​

​

Delaware ​ ​ ​ 001-35969 ​ ​ ​ 04-3416587

(State or Other Jurisdiction ​ (Commission ​ (IRS Employer

of Incorporation) ​ File Number) ​ Identification No.)

​ ​ ​

​

​

​

500 Warren Corporate Center Drive ​ ​ ​ ​ ​

Warren, NJ ​ ​ 07059

(Address of Principal Executive Offices) ​ ​ (Zip Code)

​ Registrant’s telephone number, including area code: (908) 222-7000 ​ Not applicable (Former Name or Former Address, if Changed Since Last Report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered

Common Stock, $0.001 par value per share ​

PTCT

​ Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​

Item 2.02. Results of Operations and Financial Condition. On January 12, 2026, PTC Therapeutics, Inc. (the “Company”) issued a press release (the “press release”) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2025, including that the Company expects to report (i) total unaudited net product and royalty revenue of approximately $823.4 million, (ii) total unaudited net product revenue of approximately $587.8 million, and (iii) unaudited net product revenue for Sephience™ (sepiapterin) of approximately $112.1 million. Final results are subject to completion of the Company’s year-end audit. Item 7.01. Regulation FD Disclosure. On January 12, 2026, the Company also announced financial guidance for its fiscal year ending December 31, 2026 in the press release, including that the Company anticipates (i) full year total product revenues of $700 million to $800 million, excluding Evrysdi® (risdiplam) royalty revenue and collaboration revenue and (ii) GAAP R&D and SG&A expense for the full year 2026 of $775 million to $815 million with non-GAAP R&D and SG&A expense for the full year 2026 of $680 million to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million. The Company announced that on Monday, January 12, 2026 at 12:00 p.m. EST at the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”), the Company will provide an update on 2025 accomplishments and highlight upcoming 2026 potential value-creating milestones. The Company will also present its preliminary 2025 unaudited financial results and 2026 financial guidance. The presentation will be webcast live on the Events and Presentations page under the Investors section of the Company’s website. Following the completion of the Conference, the Company will enter an investor quiet period until it provides its next corporate update. A copy of the press release and the slide presentation are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2 and are incorporated by reference into this Item 7.01. This Current Report on Form 8-K and Exhibits 99.1 and 99.2 include a forward-looking financial measure that was not prepared in accordance with accounting principles generally accepted in the United States (GAAP), non-GAAP R&D and SG&A expenses (which excludes non-cash stock-based compensation expense). Management uses this measure when assessing and identifying operational trends and, in management’s opinion, this non-GAAP measure is useful to investors and other users of its financial statements by providing greater transparency into the historical and projected operating performance of the Company and the Company’s future outlook. Non